Neurocrine Total Current Assets vs Capital Stock Analysis
NBIX Stock | USD 142.29 0.38 0.27% |
Neurocrine Biosciences financial indicator trend analysis is infinitely more than just investigating Neurocrine Biosciences recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Neurocrine Biosciences is a good investment. Please check the relationship between Neurocrine Biosciences Total Current Assets and its Capital Stock accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurocrine Biosciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Neurocrine Stock please use our How to Invest in Neurocrine Biosciences guide.
Total Current Assets vs Capital Stock
Total Current Assets vs Capital Stock Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Neurocrine Biosciences Total Current Assets account and Capital Stock. At this time, the significance of the direction appears to have very strong relationship.
The correlation between Neurocrine Biosciences' Total Current Assets and Capital Stock is 0.88. Overlapping area represents the amount of variation of Total Current Assets that can explain the historical movement of Capital Stock in the same time period over historical financial statements of Neurocrine Biosciences, assuming nothing else is changed. The correlation between historical values of Neurocrine Biosciences' Total Current Assets and Capital Stock is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Assets of Neurocrine Biosciences are associated (or correlated) with its Capital Stock. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capital Stock has no effect on the direction of Total Current Assets i.e., Neurocrine Biosciences' Total Current Assets and Capital Stock go up and down completely randomly.
Correlation Coefficient | 0.88 |
Relationship Direction | Positive |
Relationship Strength | Strong |
Total Current Assets
The total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle.Capital Stock
The total amount of a company’s capital funded by shareholders through the issue and subscription of shares.Most indicators from Neurocrine Biosciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Neurocrine Biosciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurocrine Biosciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Neurocrine Stock please use our How to Invest in Neurocrine Biosciences guide.At this time, Neurocrine Biosciences' Selling General Administrative is fairly stable compared to the past year. Tax Provision is likely to rise to about 63.8 M in 2024, whereas Issuance Of Capital Stock is likely to drop slightly above 22.9 M in 2024.
Neurocrine Biosciences fundamental ratios Correlations
Click cells to compare fundamentals
Neurocrine Biosciences Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Neurocrine Biosciences fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 1.3B | 1.7B | 2.1B | 2.4B | 3.3B | 3.4B | |
Short Long Term Debt Total | 495.5M | 412.3M | 440.4M | 262.9M | 428.4M | 449.8M | |
Other Current Liab | 156.5M | 147.1M | 194.3M | 292M | 35.9M | 42.1M | |
Total Current Liabilities | 565.3M | 186.5M | 245.8M | 537.7M | 654.8M | 687.5M | |
Total Stockholder Equity | 636.9M | 1.1B | 1.4B | 1.7B | 2.2B | 2.3B | |
Property Plant And Equipment Net | 116.2M | 127.4M | 155.8M | 145.6M | 347.3M | 364.7M | |
Net Debt | 383.2M | (388.7M) | 99.6M | 169.4M | 177.3M | 186.2M | |
Retained Earnings | (1.1B) | (725.4M) | (635.8M) | (406.8M) | (157.1M) | (165.0M) | |
Accounts Payable | 46.2M | 39.4M | 51.5M | 76.3M | 108.9M | 114.3M | |
Cash | 112.3M | 801M | 340.8M | 262.9M | 251.1M | 131.9M | |
Non Current Assets Total | 475M | 718.5M | 1.1B | 915.2M | 1.6B | 1.7B | |
Non Currrent Assets Other | 3.2M | 6.4M | 4.4M | 25M | 49.6M | 52.1M | |
Cash And Short Term Investments | 670.5M | 801M | 711.3M | 989.3M | 1.0B | 1.1B | |
Net Receivables | 126.6M | 157.1M | 185.5M | 350M | 439.3M | 461.3M | |
Common Stock Shares Outstanding | 95.7M | 97.8M | 97.9M | 98.9M | 101M | 61.8M | |
Liabilities And Stockholders Equity | 1.3B | 1.7B | 2.1B | 2.4B | 3.3B | 3.4B | |
Non Current Liabilities Total | 103.8M | 422M | 452.7M | 123.2M | 364.6M | 382.8M | |
Other Current Assets | 160.5M | 215.2M | 261.5M | 464.2M | 97.8M | 61.5M | |
Other Stockholder Equity | 1.8B | 1.8B | 2.0B | 2.1B | 2.4B | 2.5B | |
Total Liab | 669.1M | 608.5M | 698.5M | 660.9M | 1.0B | 1.1B | |
Property Plant And Equipment Gross | 116.3M | 127.4M | 155.8M | 145.6M | 430.3M | 451.8M | |
Total Current Assets | 831M | 1.0B | 972.8M | 1.5B | 1.6B | 1.7B | |
Accumulated Other Comprehensive Income | 1.4M | 1.8M | (1.7M) | (7.9M) | 7M | 7.4M | |
Short Term Debt | 408.8M | 10.3M | 16.5M | 169.4M | 170.1M | 178.6M | |
Short Term Investments | 558.2M | 613.9M | 370.5M | 726.4M | 780.5M | 819.5M | |
Other Liab | 17.1M | 9.7M | 12.3M | 29.7M | 34.2M | 24.8M | |
Other Assets | 59.1M | 674M | 319.5M | 330.9M | 380.5M | 399.6M | |
Long Term Debt | 388.5M | 408.8M | 317.9M | 335.1M | 385.4M | 404.6M | |
Common Stock Total Equity | 89K | 91K | 92K | 100K | 115K | 67.8K | |
Common Stock | 89K | 91K | 92K | 100K | 115K | 69.6K | |
Property Plant Equipment | 33.9M | 41.9M | 44.6M | 58.6M | 52.7M | 55.4M | |
Current Deferred Revenue | (46.2M) | (10.3M) | (16.5M) | 339.9M | 390.9M | 410.4M | |
Net Tangible Assets | 228.1M | 1.1B | 1.4B | 1.7B | 1.9B | 2.0B | |
Retained Earnings Total Equity | (1.1B) | (725.4M) | (635.8M) | (406.8M) | (366.1M) | (384.4M) | |
Capital Surpluse | 1.8B | 1.8B | 2.0B | 2.1B | 2.4B | 1.6B | |
Inventory | 17.3M | 28M | 30.5M | 35.1M | 38.3M | 40.2M | |
Non Current Liabilities Other | 103.8M | 104.1M | 117.6M | 29.7M | 10.3M | 9.8M | |
Long Term Investments | 299.7M | 227.1M | 560.7M | 401.5M | 849.4M | 891.9M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Neurocrine Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Neurocrine Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Neurocrine Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Neurocrine Biosciences Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurocrine Biosciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Neurocrine Stock please use our How to Invest in Neurocrine Biosciences guide.You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Complementary Tools for Neurocrine Stock analysis
When running Neurocrine Biosciences' price analysis, check to measure Neurocrine Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurocrine Biosciences is operating at the current time. Most of Neurocrine Biosciences' value examination focuses on studying past and present price action to predict the probability of Neurocrine Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurocrine Biosciences' price. Additionally, you may evaluate how the addition of Neurocrine Biosciences to your portfolios can decrease your overall portfolio volatility.
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Transaction History View history of all your transactions and understand their impact on performance |
Is Neurocrine Biosciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neurocrine Biosciences. If investors know Neurocrine will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neurocrine Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.648 | Earnings Share 3.69 | Revenue Per Share 20.147 | Quarterly Revenue Growth 0.226 | Return On Assets 0.1008 |
The market value of Neurocrine Biosciences is measured differently than its book value, which is the value of Neurocrine that is recorded on the company's balance sheet. Investors also form their own opinion of Neurocrine Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Neurocrine Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neurocrine Biosciences' market value can be influenced by many factors that don't directly affect Neurocrine Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neurocrine Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neurocrine Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neurocrine Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.